Infliximab
Brand: Remicade®, Inflectra®, Remsima®
NICE TA:
Indication: Second line biologic for moderate to severe active ulcerative colitis ONLY where patients have had adalimumab 1st line .
Disease category: Gastro-intestinal system
Commissioning responsibility: CCG
PbR excluded: Yes
Background
Infliximab or golimumab may be used as a second line biologic in UC ONLY where patients have had adalimumab 1st line.
Recommendation
LMMG recommendation: Red
Click here to find the definitions for the colour classifications
Reason for decision: Specialist medicine
Supporting documents:
Gastroenterology Biologics Pathway (Version 1.1) (355.6 KiB)
Biosimilars of Infliximab (Version 1.1) (271.7 KiB)
Decisions of Lancashire local decision making groups:
| NHS Blackburn With Darwen CCG and NHS East Lancashire CCG | NHS Blackpool CCG | NHS Chorley and South Ribble CCG and NHS Greater Preston CCG | NHS Fylde and Wyre CCG | NHS Morecambe Bay CCG | NHS West Lancashire CCG |
|---|---|---|---|---|---|
Red |
Red |
Red |
Red |
Red |
